Back to search results

PTT-936 for Locally Advanced or Metastatic Solid Tumors

This study is testing a new drug called PTT-936, either by itself or combined with existing anti-PD-1/L1 therapies, for patients with locally advanced or metastatic (spread to other parts of the body) solid tumors. The study aims to see how safe PTT-936 is and how well it works to shrink tumors or stop them from growing. You might be able to join if you are at least 18 years old and have a solid tumor that has spread or cannot be removed by surgery. The study will measure how many patients have side effects and how many see their tumors shrink or disappear. The current status of this study is unclear.

Study design
This is a Phase 1/2a study with a planned enrollment of 68 participants. It will first look at PTT-936 alone, then in combination with anti-PD-1/L1 therapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes like side effects and tumor response for 7 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06244992

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Pyrotech Therapeutics, Inc.
~68 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:PTT-936Combination of PTT-936 and anti-PD-1/L1 therapy

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of TEAEs and TRAEs (with severity determined using NCI CTCAE v5.0), Grade >3 TEAEs, Grade >3 TRAEs, SAEs, and AESIs
Measured over 7 months
+1 more outcome measured

Conditions

Locally Advanced or Metastatic Solid Tumors

Explore related trials

Solid Neoplasm

NCT06244992

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Beijing Cancer Hospital

    Beijing, Chinastudy coordinator listed

    Recruiting

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Chinastudy coordinator listed

    Recruiting

  • D&H Cancer Research Center

    Margate, Floridastudy coordinator listed

    Recruiting

  • Precision NextGen Oncology and Research Center

    Beverly Hills, Californiastudy coordinator listed

    Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, Chinastudy coordinator listed

    Recruiting

  • The START Center

    San Antonio, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Rebecca Godin, RN, BSN
[email protected]
(424)777-0708
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of TEAEs and TRAEs (with severity determined using NCI CTCAE v5.0), Grade >3 TEAEs, Grade >3 TRAEs, SAEs, and AESIs7 months
  • Overall Response Rate (ORR): defined as the percentage of patients who achieved Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 and iRECIST during the study7 months